Molecular Imaging of Lymphoma: Future Directions and Perspectives

More than 250,000 patients die from Hodgkin or non-Hodgkin lymphoma each year. Currently, molecular imaging with 18F-FDG-PET/CT is the standard of care for lymphoma staging and therapy response assessment. In this review, we will briefly summarize the role of molecular imaging for lymphoma diagnosis...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in nuclear medicine 2023-05, Vol.53 (3), p.449-456
Main Authors: Pomykala, Kelsey L., Fendler, Wolfgang P., Vermesh, Ophir, Umutlu, Lale, Herrmann, Ken, Seifert, Robert
Format: Article
Language:English
Subjects:
Artificial Intelligence
Fluorodeoxyglucose F18
Hodgkin Disease - therapy
Humans
Lymphoma - diagnostic imaging
Lymphoma - pathology
Lymphoma - therapy
Molecular Imaging
Neoplasm Staging
Positron Emission Tomography Computed Tomography - methods
Positron-Emission Tomography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:More than 250,000 patients die from Hodgkin or non-Hodgkin lymphoma each year. Currently, molecular imaging with 18F-FDG-PET/CT is the standard of care for lymphoma staging and therapy response assessment. In this review, we will briefly summarize the role of molecular imaging for lymphoma diagnosis, staging, outcome prediction, and prognostication. We discuss future directions in response assessment and surveillance with quantitative PET parameters, the utility of interim assessment, and the differences with response assessment to immunomodulatory therapy. Lastly, we will cover innovations in the field regarding novel tracers and artificial intelligence.
ISSN:0001-2998
1558-4623
DOI:10.1053/j.semnuclmed.2022.10.003